124 related articles for article (PubMed ID: 16397274)
1. Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells.
Olver S; Groves P; Buttigieg K; Morris ES; Janas ML; Kelso A; Kienzle N
Cancer Res; 2006 Jan; 66(1):571-80. PubMed ID: 16397274
[TBL] [Abstract][Full Text] [Related]
2. Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization.
Bour H; Horvath C; Lurquin C; Cerottini JC; MacDonald HR
J Immunol; 1998 Jun; 160(11):5522-9. PubMed ID: 9605156
[TBL] [Abstract][Full Text] [Related]
3. IFN-gamma inhibits IL-4-induced type 2 cytokine expression by CD8 T cells in vivo and modulates the anti-tumor response.
Apte SH; Groves P; Olver S; Baz A; Doolan DL; Kelso A; Kienzle N
J Immunol; 2010 Jul; 185(2):998-1004. PubMed ID: 20562261
[TBL] [Abstract][Full Text] [Related]
4. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
Ye Z; Shi M; Chan T; Sas S; Xu S; Xiang J
Cancer Gene Ther; 2007 Jul; 14(7):661-75. PubMed ID: 17479109
[TBL] [Abstract][Full Text] [Related]
5. The duplicitous effects of interleukin 4 on tumour immunity: how can the same cytokine improve or impair control of tumour growth?
Olver S; Apte S; Baz A; Kienzle N
Tissue Antigens; 2007 Apr; 69(4):293-8. PubMed ID: 17389011
[TBL] [Abstract][Full Text] [Related]
6. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
7. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro.
Gajewski TF; Renauld JC; Van Pel A; Boon T
J Immunol; 1995 Jun; 154(11):5637-48. PubMed ID: 7538528
[TBL] [Abstract][Full Text] [Related]
8. CD8-interaction mutant HLA-Cw3 molecules protect porcine cells from human natural killer cell-mediated antibody-dependent cellular cytotoxicity without stimulating cytotoxic T lymphocytes.
Sharland A; Lee JH; Saidman S; Waneck GL
Transplantation; 2003 Dec; 76(11):1615-22. PubMed ID: 14702534
[TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses.
Liu Y; Bi X; Xu S; Xiang J
Cancer Res; 2005 Jun; 65(11):4955-62. PubMed ID: 15930318
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.
Ley V; Langlade-Demoyen P; Kourilsky P; Larsson-Sciard EL
Eur J Immunol; 1991 Mar; 21(3):851-4. PubMed ID: 2009918
[TBL] [Abstract][Full Text] [Related]
11. Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity.
Søndergaard H; Coquet JM; Uldrich AP; McLaughlin N; Godfrey DI; Sivakumar PV; Skak K; Smyth MJ
J Immunol; 2009 Dec; 183(11):7326-36. PubMed ID: 19915059
[TBL] [Abstract][Full Text] [Related]
12. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.
Dubsky P; Saito H; Leogier M; Dantin C; Connolly JE; Banchereau J; Palucka AK
Eur J Immunol; 2007 Jun; 37(6):1678-90. PubMed ID: 17492620
[TBL] [Abstract][Full Text] [Related]
13. Interferon-gamma and interleukin-4 reciprocally regulate CD8 expression in CD8+ T cells.
Apte SH; Baz A; Groves P; Kelso A; Kienzle N
Proc Natl Acad Sci U S A; 2008 Nov; 105(45):17475-80. PubMed ID: 18988742
[TBL] [Abstract][Full Text] [Related]
14. The induction of in vivo proliferation of long-lived CD44hi CD8+ T cells after the injection of tumor cells expressing IFN-alpha1 into syngeneic mice.
Belardelli F; Ferrantini M; Santini SM; Baccarini S; Proietti E; Colombo MP; Sprent J; Tough DF
Cancer Res; 1998 Dec; 58(24):5795-802. PubMed ID: 9865738
[TBL] [Abstract][Full Text] [Related]
15. CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism.
Yang T; Wall EM; Milne K; Theiss P; Watson P; Nelson BH
Clin Cancer Res; 2007 Dec; 13(23):7172-80. PubMed ID: 18056198
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
17. A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity.
Huber M; Heink S; Grothe H; Guralnik A; Reinhard K; Elflein K; Hünig T; Mittrücker HW; Brüstle A; Kamradt T; Lohoff M
Eur J Immunol; 2009 Jul; 39(7):1716-25. PubMed ID: 19544308
[TBL] [Abstract][Full Text] [Related]
18. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
Chen PW; Ksander BR
Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells.
Sabel MS; Arora A; Su G; Mathiowitz E; Reineke JJ; Chang AE
Surgery; 2007 Nov; 142(5):749-60. PubMed ID: 17981196
[TBL] [Abstract][Full Text] [Related]
20. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
